See more : Excel Industries Limited (EXCELINDUS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Shandong Sito Bio-technology Co., Ltd. (300583.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shandong Sito Bio-technology Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- China Green Agriculture, Inc. (CGA) Income Statement Analysis – Financial Results
- NetPay International, Inc. (NTPY) Income Statement Analysis – Financial Results
- Aerojet Rocketdyne Holdings, Inc. (AJRD) Income Statement Analysis – Financial Results
- Lloyds Banking Group plc (LLDTF) Income Statement Analysis – Financial Results
- Impel Pharmaceuticals Inc. (IMPL) Income Statement Analysis – Financial Results
Shandong Sito Bio-technology Co., Ltd. (300583.SZ)
About Shandong Sito Bio-technology Co., Ltd.
Shandong Sito Bio-technology Co., Ltd. researches and develops new steroid hormones, intermediates, and derivatives. Its products include 9a-hydroxyandrostenedione, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, dexamethasone epoxy hydrolysate, progesterone intermediate, opener, tetraene, androstenedione, ketal, acid removal, 3-ketal, and betamethasone epoxy hydrolyzate, as well as 1,4-androstenedione. The company was founded in 2002 and is based in Heze, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.28B | 1.31B | 1.20B | 913.19M | 965.80M | 1.05B | 785.57M | 568.25M | 668.17M | 521.01M | 283.59M | 11.03M |
| Cost of Revenue | 1.01B | 1.04B | 937.04M | 805.58M | 730.08M | 784.76M | 602.94M | 377.22M | 372.53M | 278.94M | 199.50M | 9.02M |
| Gross Profit | 268.31M | 272.81M | 265.59M | 107.61M | 235.72M | 267.52M | 182.62M | 191.03M | 295.64M | 242.07M | 84.08M | 2.01M |
| Gross Profit Ratio | 20.97% | 20.79% | 22.08% | 11.78% | 24.41% | 25.42% | 23.25% | 33.62% | 44.25% | 46.46% | 29.65% | 18.24% |
| Research & Development | 55.08M | 50.21M | 49.73M | 45.01M | 55.79M | 39.42M | 31.66M | 19.15M | 22.67M | 16.82M | 10.09M | 0.00 |
| General & Administrative | 42.83M | 37.27M | 35.32M | 30.99M | 31.04M | 34.21M | 14.45M | 9.36M | 9.52M | 6.26M | 2.25M | 2.59M |
| Selling & Marketing | 5.38M | 14.61M | 13.76M | 15.48M | 12.25M | 9.97M | 11.19M | 6.00M | 5.84M | 4.35M | 2.40M | 35.76K |
| SG&A | 48.21M | 51.88M | 49.08M | 46.47M | 43.29M | 44.18M | 25.65M | 15.35M | 15.36M | 10.61M | 4.64M | 2.63M |
| Other Expenses | 132.29M | -1.31M | -1.68M | -6.29M | -2.49M | -388.27K | 23.90K | 1.44M | -204.05K | 7.99M | 1.06M | -406.95 |
| Operating Expenses | 235.57M | 189.13M | 168.53M | 187.12M | 149.18M | 121.55M | 89.90M | 60.96M | 58.56M | 38.73M | 19.40M | 2.63M |
| Cost & Expenses | 1.25B | 1.23B | 1.11B | 992.70M | 879.27M | 906.31M | 692.84M | 438.18M | 431.09M | 317.67M | 218.91M | 11.65M |
| Interest Income | 4.74M | 3.71M | 2.66M | 1.62M | 1.27M | 1.11M | 2.62M | 248.36K | 401.04K | 238.79K | 212.22K | -0.39 |
| Interest Expense | 40.86M | 36.89M | 30.21M | 33.98M | 31.08M | 20.70M | 7.52M | 12.39M | 12.95M | 8.41M | 5.99M | 821.38K |
| Depreciation & Amortization | 173.57M | 107.58M | 135.70M | 143.12M | 82.89M | 68.05M | 62.71M | 45.01M | 34.11M | 16.92M | 2.93M | 1.20M |
| EBITDA | 264.71M | 190.26M | 217.76M | -17.31M | 179.92M | 222.19M | 175.68M | 161.20M | 254.33M | 220.02M | 64.91M | -430.58K |
| EBITDA Ratio | 20.68% | 19.46% | 19.58% | 7.17% | 18.49% | 22.43% | 21.98% | 30.58% | 40.38% | 42.23% | 24.27% | -3.90% |
| Operating Income | 32.74M | 49.22M | 55.97M | -186.16M | 67.19M | 149.94M | 103.24M | 114.43M | 218.23M | 195.95M | 54.92M | -1.63M |
| Operating Income Ratio | 2.56% | 3.75% | 4.65% | -20.39% | 6.96% | 14.25% | 13.14% | 20.14% | 32.66% | 37.61% | 19.37% | -14.76% |
| Total Other Income/Expenses | 20.74M | -1.31M | -1.68M | -6.29M | -2.49M | -1.60M | 23.91K | 1.44M | -288.86K | -1.91M | 1.06M | -406.95 |
| Income Before Tax | 53.48M | 47.91M | 54.29M | -192.45M | 64.71M | 149.55M | 103.27M | 115.85M | 217.94M | 194.04M | 55.99M | -1.63M |
| Income Before Tax Ratio | 4.18% | 3.65% | 4.51% | -21.07% | 6.70% | 14.21% | 13.15% | 20.39% | 32.62% | 37.24% | 19.74% | -14.76% |
| Income Tax Expense | 4.93M | 5.43M | 18.50M | -2.83M | 15.66M | 22.60M | 17.51M | 19.50M | 32.08M | 28.29M | 14.43M | -135.34K |
| Net Income | 45.60M | 41.97M | 36.21M | -179.81M | 55.31M | 126.85M | 92.00M | 101.18M | 187.04M | 165.75M | 41.56M | -1.49M |
| Net Income Ratio | 3.56% | 3.20% | 3.01% | -19.69% | 5.73% | 12.05% | 11.71% | 17.81% | 27.99% | 31.81% | 14.66% | -13.53% |
| EPS | 0.25 | 0.25 | 0.21 | -1.05 | 0.33 | 1.19 | 0.88 | 1.26 | 2.34 | 2.07 | 0.52 | 0.00 |
| EPS Diluted | 0.25 | 0.25 | 0.21 | -1.05 | 0.33 | 1.19 | 0.88 | 1.26 | 2.34 | 2.07 | 0.52 | 0.00 |
| Weighted Avg Shares Out | 182.42M | 171.08M | 171.08M | 171.08M | 170.18M | 106.85M | 104.55M | 80.30M | 79.93M | 80.07M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 182.42M | 171.08M | 171.08M | 171.08M | 170.18M | 106.85M | 104.55M | 80.30M | 79.93M | 80.07M | 0.00 | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports